FAQ

rivastigmine 1.5 MG Oral Capsule

Known as: rivastigmine 1.5 MG (as rivastigmine tartrate 2.4 MG) Oral Capsule, RIVASTIGMINE TARTRATE 1.5 mg ORAL CAPSULE [Rivastigmine Tartrate], RIVASTIGMINE TARTRATE 1.5MG CAP,UD 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2013
0120072013

Related topics

Related topics

28 relations
1-ButanolAlzheimer's DiseaseAmmoniaCarbamates
(More)

Related mentions per year

Related mentions per year

1936-2019
19401960198020002020
rivastigmine 1.5 MG Oral Capsule
Ethanol
Alzheimer's Disease
Hypersensitivity
Silicon Dioxide
Sodium Dodecyl Sulfate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
BACKGROUND Cognitive decline has been recognised as a frequent symptom in multiple sclerosis (MS). Cholinesterase inhibitors… (More)
Is this relevant?
2007
2007
No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats
[123I]FP-CIT SPECT is a valuable diagnostic tool to discriminate Lewy body dementia from Alzheimer’s dementia. To date, however… (More)
  • figure 1
Is this relevant?